Nantes University Hospital: Multiple Myeloma trials

The registry lists 18 Multiple Myeloma studies with Nantes University Hospital as lead sponsor. 3 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 8Phase 3 3No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)Not yet recruitingNCT06931704Phase 2
• Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma PatientsRecruitingNCT03832127Phase 1
• MYeloma Resistance And Clonal EvolutionRecruitingNCT03807128
• Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot StudyCompletedNCT06418750Not applicable
• Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple MyelomaActive, not recruitingNCT06353022Phase 2
• Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.WithdrawnNCT05321862Phase 2
• A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."Active, not recruitingNCT04998786Phase 2
• Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple MyelomaActive, not recruitingNCT04561492Phase 2
• An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma PatientsActive, not recruitingNCT03606577Phase 2
• Collection of Additional Data Followed the Study IFM 2013-04Status unknownNCT03089411
• Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.TerminatedNCT02063113Not applicable
• Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)CompletedNCT01971658Phase 3
• Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)CompletedNCT01936532Phase 2
• Imaging Young Myeloma (IMAgerie JEune Myélome)CompletedNCT01309334Phase 3
• Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaTerminatedNCT00337506Phase 2
• Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple MyelomaCompletedNCT00291538Phase 1
• IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple MyelomaCompletedNCT00200681Phase 3
• Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.TerminatedNCT00200668Not applicable